Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

117.72 +4.59 (+4.06%)
Streaming Delayed Price Updated: 2:22 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
65 66 Next >
Why BioNTech Was a Sickly Stock This Week
The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks. 
Via The Motley Fool
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
Three Pharma Stocks to Sell Before They Die
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
From BioNTech SE
Via GlobeNewswire
BioNTech Starts Dosing In Herpes Vaccine Candidate Study
Via Benzinga
Will Investors Notice Exciting Sign On BioNTech's Chart?
Via Benzinga
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
From BioNTech SE
Via GlobeNewswire
Update on First BioNTainer for African-based mRNA Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates
Via Benzinga
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
From BioNTech SE
Via GlobeNewswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
Via Benzinga
Why Is Novavax (NVAX) Stock Plunging Today?
NVAX stock is down today on fundraising plans. Here's what investors should know about this once-promising Covid-19 vaccine player. 
Via InvestorPlace
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry
At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030. 
Via Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
From BioNTech SE
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old
Via Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From BioNTech SE
Via GlobeNewswire
US Supports Delay On COVID Patent Waiver Extension Decision
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health... 
Via Benzinga
UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids
Via Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
From BioNTech SE
Via GlobeNewswire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These two companies are facing short-term issues that are likely to give way to long-term success. 
Via The Motley Fool
Is Novavax Stock a Buy Now?
There's probably not much good news coming for this biotech in the near future. 
Via The Motley Fool
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.